Prescribing trends of adjuvant neratinib in hormone-positive HER2 positive breast cancer. Blanter J, Kocyigit H, Kowtha L, Harigopal M, et al. Oncology 2026 Jan 7:1-10. doi: 10.1159/000549970.

Read + Share

Amedeo Smart

Independent Medical Education

Blanter J, Kocyigit H, Kowtha L, Harigopal M, et al. Prescribing trends of adjuvant neratinib in hormone-positive HER2 positive breast cancer. Oncology 2026 Jan 7:1-10. doi: 10.1159/000549970.
PMID: 41499317